中文摘要：

目的纯化鉴定应用固定金属亲和芯片（IMAC30）筛选的潜在卵巢恶性肿瘤血清标志物M7784和M7837，确定其临床诊断价值。方法根据潜在血清标志物蛋白质特性，采用亲和、分子排阻、阴离子、阳离子交换、反向等一系列柱层析方法，收集组分IMAC30芯片监测，激光解析时间飞行质谱鉴定纯化的潜在标志蛋白。应用酶联免疫吸附检测潜在血清标记物在59例卵巢恶性肿瘤患者，64例卵巢良性肿瘤患者，142例健康妇女血清中的含量，应用免疫组化研究其在26例恶性肿瘤患者、11例良性肿瘤患者和8例正常卵巢组织中的表达情况。结果M7784蛋白质鉴定结果为人趋化因子配体18（CCL18）；M7837蛋白质被鉴定人CXC趋化连接因子1（CXCL1）。卵巢恶性肿瘤患者血清CCL18值为（150±62）ng／ml，CXCL1表达量为（1．0±0．4）ng／ml，明显高于良性肿瘤患者及正常人群（P〉0．01），它们联合建立的诊断模型灵敏度和特异度达100％。免疫组化结果表明在卵巢组织的恶性病变细胞胞质中明显高表达，正常组织不表达。结论以CXCL1和CCL18两个指标建立的诊断模型可应用于卵巢恶性肿瘤早期筛查。

英文摘要：

Objective To identify practical biomarkers used in diagnosis of ovarian cancer. Methods Peripheral blood samples were collected from 59 ovarian cancer patients, 64 ovarian benign tumors patients, and 142 healthy women and underwent column chromatography to purify the target proteins. The proteins thus obtained were identified with matrix-assisted desorptional ionization tissue-of-flight mass spectrometry （MALDI-TOF MS）. Immunohistochemistry was used to detect the expression of CCL18 and CXCL1 in the cancer tissues. ELISA was used to detect the serum CCl18 and CXCL1 contents. Receiver operating characteristic curve was drawn to examine the sensitivity and specificity of the potential biomarker to ovarian cancer. Results The m/z 7 784 and 7 837 proteins were identified as chemokine CC2 motif ligand 18 （CCL18） and CXC Chemokines ligand 1 （CXCL1） respectively. The serum levels of CCL18 and CXCL1 of the patients with ovarian caner were 150 ± 62 ng/ml and 1 ± 0. 4 ng/ml respectively, both were significantly higher than those of the healthy control women and the patients with ovarian benign diseases （ all P 〈0. 05）. The diagnostic sensitivity and specificity of CXCL1 to ovarian cancer were 100% and 97. 8% respectively. The diagnostic sensitivity of CCL18 was 100% to ovarian cancer of stages Ⅰ - Ⅱand 86. 1% to ovarian cancer of stages Ⅲ - Ⅳ. The CCL18 positive rate in the cancer tissue was 84. 6% and the CXCL1 expression rate was 96.2% . The model established based the combination of both biomarkers had the sensitivity and specificity to ovarian cancer of both 100%. Conclusion CCL18 and CXCL1 may be used in eady screening of ovarian cancer.